Identification of Genetic Markers for Cardiopulmonary Diseases (Genotype)
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 15 - Any |
| Updated: | 4/21/2016 |
| Start Date: | January 2008 |
| End Date: | January 2015 |
Identification of Genetic Markers for Cardiopulmonary Diseases
This study is designed to investigate whether an association exists between certain
genes/protein levels and the development of various cardiopulmonary diseases. It is hoped
that this project will provide valuable insight into the understanding of these diseases.
genes/protein levels and the development of various cardiopulmonary diseases. It is hoped
that this project will provide valuable insight into the understanding of these diseases.
There are two main groups of participants in this trial:
Group 1: Patients that are enrolled in either or both of previous studies: X980515002 study
(Identification of Genetic Markers for Primary Pulmonary Hypertension) and or X030403017
study (Pulmonary Arterial Hypertension (PAH) Database)
Group 2: Participants with the diagnosis of any of the previously listed Cardiopulmonary
Diseases who are ≥15 years of age
Group 1: For those patients who have had blood samples drawn as a result of participating in
the current protocol, Identification of Genetic Markers for Primary Pulmonary Hypertension
study (X980515002), we would like to use their previously obtained blood and continue to
draw samples (12mL; less than 3 tablespoons) ONLY if they change disease therapies. With
each disease therapy change, blood will be drawn at baseline, at 3-4 month, at 6-8 month, at
12 month, and at 24 month visits. These current X980515002 participants WILL sign a consent
form to participate in this new trial. As for the X980515002 expired patients, we would like
to use the previously obtained data ONLY in part for this study that was collected as a
result of the X980515002 study.
For those patients who participated in Pulmonary Arterial Hypertension (PAH) Database study
(X030403017), these participants WILL also sign a consent form to participant in this new
trial. We would like to use the previously obtained data from the X030403017 in part with
this study. With each disease therapy change, a 12mL (less than 3 teaspoons) blood sample
will be drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at 24 month visits.
As for the X030403017 expired patients, we would like to use the previously obtained data in
part for this study that was collected as a result of the X030403017 study.
Group 2: After signing a consent form, these participants will have a 12mL (less than 3
teaspoons) blood sample drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at
24 month visits. With each disease therapy change, the blood draws (12mL samples) will begin
again at baseline and continue through the 3-4, 6-8, 12, and 24 month visits.
Group 1: Patients that are enrolled in either or both of previous studies: X980515002 study
(Identification of Genetic Markers for Primary Pulmonary Hypertension) and or X030403017
study (Pulmonary Arterial Hypertension (PAH) Database)
Group 2: Participants with the diagnosis of any of the previously listed Cardiopulmonary
Diseases who are ≥15 years of age
Group 1: For those patients who have had blood samples drawn as a result of participating in
the current protocol, Identification of Genetic Markers for Primary Pulmonary Hypertension
study (X980515002), we would like to use their previously obtained blood and continue to
draw samples (12mL; less than 3 tablespoons) ONLY if they change disease therapies. With
each disease therapy change, blood will be drawn at baseline, at 3-4 month, at 6-8 month, at
12 month, and at 24 month visits. These current X980515002 participants WILL sign a consent
form to participate in this new trial. As for the X980515002 expired patients, we would like
to use the previously obtained data ONLY in part for this study that was collected as a
result of the X980515002 study.
For those patients who participated in Pulmonary Arterial Hypertension (PAH) Database study
(X030403017), these participants WILL also sign a consent form to participant in this new
trial. We would like to use the previously obtained data from the X030403017 in part with
this study. With each disease therapy change, a 12mL (less than 3 teaspoons) blood sample
will be drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at 24 month visits.
As for the X030403017 expired patients, we would like to use the previously obtained data in
part for this study that was collected as a result of the X030403017 study.
Group 2: After signing a consent form, these participants will have a 12mL (less than 3
teaspoons) blood sample drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at
24 month visits. With each disease therapy change, the blood draws (12mL samples) will begin
again at baseline and continue through the 3-4, 6-8, 12, and 24 month visits.
Inclusion Criteria:
- Participants with the diagnosis of any of the previously listed Cardiopulmonary
Diseases who are ≥15 years of age will be approached and offered the opportunity to
participate in this study.
We found this trial at
1
site
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
